Risk stratification for the prevention of cardiovascular complications of hypertension

Current Medical Research and Opinion

Volumn 20, Issue 7, 2004, Pages 1137-1142

  Girerd, Xavier ^a   Giral, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antihypertensive treatments; Cardiovascular risk; Outcome trials; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG CHOICE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SHORT SURVEY; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 3242701628     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004169     Document Type: Short Survey

References (28)

1. McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease-mortality, morbidity, medical care and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 1996;334:884-90
2. Chobanian AV, Bakris GL, Black HR, Cushman WC. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-71
3. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6
4. Guidelines Committee.2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053
5. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10
6. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-362
7. Collins R, Peto R, McMahon S, et al. Blood pressure, stroke, and coronary artery disease. Part 2, short-term reductions in blood pressure: overview of randomized trials in their epidemiological context. Lancet 1990;335:827-38
8. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomised controlled trials. The INDANA investigators. Ann Intern Med 1997;126:761-7
9. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
10. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21
11. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation 2002;106:388-391
12. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64
13. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
14. Reynolds TM, Twomey PJ, Wierzbicki AS. Concordance evaluation of coronary risk scores: implication for cardiovascular risk screening. Cur Med Res Opin 2004;20:811-18
15. Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002;20:1973-80
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15
17. Mac Mahon S, Peto R Cutler J, et al. Blood pressure, stroke, and coronary artery disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74
18. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72
19. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003;362:782-8
20. Lithell H, Hansson L, Skoog I, et al. The study on Cognition and Prognosis in then Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised trial. Lancet 2002;360:1623-30
22. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342-9
23. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
24. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361:1149-58
25. Downs JR, Clearfield M, Weis, S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22
26. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
27. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatine in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
28. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels for high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8